Impact of external price referencing on medicine prices - A price comparison among 14 European countries

Southern Med Review

Volumn 5, Issue 2, 2012, Pages 34-41

  Leopold, Christine ^a   Mantel Teeuwisse, Aukje Katja ^b   Seyfang, Leonhard ^a   Vogler, Sabine ^a   de Joncheere, Kees ^c   Laing, Richard Ogilvie ^c   Leufkens, Hubert ^b  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b UTRECHT UNIVERSITY   (Netherlands)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Europe; External price referencing; Medicines; Prices; Pricing policy

Indexed keywords

ABACAVIR; CAPECITABINE; CELSENTRL; DARUNAVIR; EFAVIRENZ; ENOXAPARIN; FONDAPARINUX; FOSAMPRENAVIR; MARAVIROC; PARLET; PIOGLITAZONE; RABEPRAZOLE; ROSIGLITAZONE; SIBUTRAMINE; TENOFOVIR DISOPROXIL; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VLREAD; ZELODA; ZLAGEN;

ARTICLE; AUSTRIA; BELGIUM; CAPITAL; DENMARK; DRUG CAPSULE; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; EUROPE; EXTERNAL PRICE REFERENCING; FINLAND; FRANCE; GERMANY; GREECE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; ITALY; NETHERLANDS; NORWAY; PATENT; PORTUGAL; REIMBURSEMENT; SLOVAKIA; SPAIN; SWEDEN; TABLET;

EID: 84874262540     PISSN: 11742704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Marquis MS, Phelps CE. Price Elasticity and Adverse Selection in the Demand for Supplementary Health Insurance. Economic Inquiry. 1987 April; 25(2):299-313.
2. Brekke K, Holmas TH, Straume OR. Are pharmaceuticals inexpensive in Norway? A comparison of prices of prescription pharmaceuticals between Norway and nine west European countries. Institute for Research in Economics and Business Administration. 2008 May.
3. Docteur E, Paris V. Pharmaceutical Pricing Policies in a global market. Paris. OECD Health Policy Studies. 2007; Available from: http://www.oecd.org/document/44/0,3343,en_2649_37407_41382764_1_1_1_1,00.html.
4. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. 2011; IP/A/ENVI/ST/2010-12. European Parliament, Brussels.
5. Vogler S, Habl C, Leopold C, Rosian-Schikuta I. PPRI Report. Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG, 2008.
6. Vogler S. Preisbildung und Erstattung von Arzneimitteln in der EU - Gemeinsamkeiten, Unterschiede und Trends. Pharmazeutische Medizin. 2012;14(1):48-56.
7. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. External Price Referencing in Europe - a descriptive overview of one policy with many national characteristics. Health Policy. 2012:104(1):60. Epub 2001/10/22.
8. Espin J, Rovira J, De Labry AO. External Reference Pricing, WHO/HAI Project on Medicine Prices and Availability. WHO review series on Pharmaceutical Pricing Policies and Interventions, Working Paper. 2011.
9. Heuer A, Mejer M, Neuhaus J. The National Regulation of Pharmaceutical Markets and the Timing of New Drug Launches in Europe. Institute for the World Economy Working Paper No. 437. 2007. Available from: http://www.ifw-kiel.de/ausbildung/asp/asp-wp/2007/aspwp437.pdf.
10. Mariñoso BG, Jelovac I, Olivella P. External referencing and pharmaceutical price negotiation. GATE Groupe d'Analyse et de Théorie Économique. Working paper 08-15. 2008. Available from: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1168822.
11. Stargardt T, Schreyögg J. The impact of cross-reference pricing on pharmaceutical prices - manufacturers' pricing strategies and price regulation. Appl Health Econ Health Policy. 2006;5(4):235-47.
12. Richter A. Assessing the impact of global price interdependencies. Pharmacoeconomics. 2008;26(8):649-59.
13. Windmeijer F, de Laat E, Douven R, Mot E. Pharmaceutical promotion and GP prescription behavior. Health Econ. 2006 Jan;15 (1)5-18.
14. Merkur S, Mossialos E. A pricing policy towards the sourcing of cheaper drugs in Cyprus. Health Policy; 2007 May;81(2-3):368-75. Epub 2006 Sep 1.
15. Filko M, Szilagyiova P. The Slovak experience in the international price benchmarking for prescription drugs. Value in Health; 2009;12(7):229-230.
16. Kaiser U, Mendez SJ, Ronde T. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark. Centre for European Economic Research. Discussion Paper No. 10-062. Available from: ftp://ftp.zew.de/pub/zew-docs/dp/dp10062.pdf.
17. Kyle MK. The Role of Firm Characteristics in Pharmaceutical Product Launches. The RAND Journal of Economics. 2006;37(3):602-618.
18. European Medicine Agency. [updated 2012; cited 2012/1/05]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124.
19. PPRI network members. PPRI / PHIS Pharma Profiles. Available from: http://whocc.goeg.at/Publications/CountryReports. PPRI (Pharmaceutical Pricing and Reimbursement Information), 2007-2011.
20. Pharmaceutical Price Information (PPI), Austrian Health Institute. [updated 2012/08/01; cited 2012/01/05]. Available from: http://www.goeg.at/en/Reports-Service.html.
21. IMS Health Institute.
22. OECD Health database. Available from: http://www.oecd.org/document/19/0,3746,en_21571361_33915056_39091923_1_1_1_1,00.htm
23. European Federation of Pharmaceutical Industry Association (EFPIA). [updated 2012/08/01; cited 2012/01/05]. Available from: http://www.efpia.eu/content/default.asp?PageID=559&DocID=9158.
24. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2010. Vienna, Austria. ISBN 3-900051-07-0 Available from: http://www.R-project.org.
25. Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N. PHIS Hospital Pharma Report. Vienna: Pharmaceutical Health Information System; Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG, 2010.
26. Costa-i-Font J, Kanavos P. Medicines in parallel trade in the European Union: a gravity specification. LSE Health working papers. 2007 June. London School of Economics and Political Science, London, UK.
27. Glynn D. The effects of parallel trade on affordable access to medicines. Eurohealth. 2009;15(2):1-4.
28. Rosian I, Vogler S, Internationale Arzneimittelpreisvergleiche - Meta-Analyse. ÖBIG. 2004.
29. Danzon PM, Chao LW, Cross-national price differences for pharmaceuticals: how large, and why? Journal of Health Economics. 2000; 19(2) 159-195.
30. Danzon PM, Wang RY, Wang L. The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s. Health Economics. 2005;14(3):269-92.
31. European Commission. Pharmaceutical Sector Inquiry. 2008. Available from: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html le online.